Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor

被引：0
|
作者：
Simon J. B. Aylwin
Istvan Bodi
Ronald Beaney
机构：
[1] King’s College Hospital,Department of Endocrinology
[2] King’s College Hospital,Department of Clinical Neuropathology
[3] Guy’s & St Thomas’ Hospital Cancer Centre,Department of Neuro
来源：
Pituitary | 2016年 / 19卷
关键词：
Vemurafenib; Craniopharyngioma; Prolactinoma; BRAF Inhibitor; BRAF V600E Mutation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：544 / 546
页数：2
相关论文
共 50 条
  • [41] Case History: Vemurafenib, a Potent, Selective, and First-in-Class Inhibitor of Mutant BRAF for the Treatment of Metastatic Melanoma
    Ibrahim, Prabha N.
    Zhang, Jiazhong
    Zhang, Chao
    Bollag, Gideon
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 48, 2013, 48 : 435 - 449
  • [42] Use of Vemurafenib, a BRAF Inhibitor Along With Radiation Therapy in Melanoma Brain Metastasis
    Narayana, A.
    Mathew, M.
    Golfinos, J. G.
    Parker, E. C.
    Ott, P.
    Pavlick, A. C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S302 - S303
  • [43] Bilateral panuveitis in a patient on vemurafenib BRAF inhibitor therapy for stage IV melanoma
    Agemy, Steven A.
    Mehta, Ankur N.
    Pachydaki, Sophia I.
    Tewari, Asheesh
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2014, 24 (04) : 629 - 632
  • [44] Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
    Atzori, Maria Grazia
    Ceci, Claudia
    Ruffini, Federica
    Trapani, Mauro
    Barbaccia, Maria Luisa
    Tentori, Lucio
    D'Atri, Stefania
    Lacal, Pedro Miguel
    Graziani, Grazia
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (01) : 465 - 475
  • [45] BRAF-Inhibitor Vemurafenib verlängert progressionsfreies und Gesamtüberleben
    best practice onkologie, 2011, 6 (4) : 22 - 22
  • [46] Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies
    Subbiah, Vivek
    Sen, Shiraj
    Hess, Kenneth R.
    Janku, Filip
    Hong, David S.
    Khatua, Soumen
    Karp, Daniel D.
    Munoz, Javier
    Falchook, Gerald S.
    Groisberg, Roman
    Tsimberidou, Apostolia M.
    Sherman, Steven, I
    Hwu, Patrick
    Meric-Bernstam, Funda
    JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 12
  • [47] Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
    del Carmen Alamo, Ma
    Ochenduszko, Sebastian
    Crespo, Guillermo
    Corral, Monica
    Oramas, Juana
    Sancho, Pilar
    Medina, Javier
    Garicano, Fernando
    Lopez, Pedro
    Campos Balea, Begona
    Rodriguez Garzotto, Analia
    Munoz-Couselo, Eva
    ONCOTARGETS AND THERAPY, 2021, 14 : 5345 - 5352
  • [48] EVALUATION OF HO-1 INVOLVEMENT IN MELANOMA RESISTANCE TO BRAF INHIBITOR VEMURAFENIB
    Loi, Giulia
    Furfaro, AnnaLisa
    Pronzato, Maria Adelaide
    Pietra, Gabriella
    Nitti, Mariapaola
    POSTGRADUATE MEDICAL JOURNAL, 2018, 94 : A6 - A6
  • [49] Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia
    Park, Jae H.
    Chung, Stephen S.
    Chung, Young Rock
    Won, Helen
    Teruya-Feldstein, Julie
    Berger, Michael
    Khawaja, Talal T.
    Lacouture, Mario E.
    Levine, Ross L.
    Abdel-Wahab, Omar
    Tallman, Martin S.
    BLOOD, 2013, 122 (21)
  • [50] High Incidence of Naevi-associated BRAF Wild-type Melanoma and Dysplastic Naevi under Treatment with the Class I BRAF Inhibitor Vemurafenib
    Goeppner, Daniela
    Mueller, Jan
    Krueger, Sabine
    Franke, Ingolf
    Gollnick, Harald
    Quist, Sven R.
    ACTA DERMATO-VENEREOLOGICA, 2014, 94 (05) : 517 - 520
12345